Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/6/2026

1. ZS
2. LULU
3. IOT
4. SPY
5. PATH
6. DOCU
7. ASAN
8. NVDA
9. CIEN
10. GWRE

Go back to Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
(NASDAQ: BMEA) Delayed: 2.03 +0.12 (6.28%)
Previous Close $1.91    52 Week High $ 
Open $1.90    52 Week Low $ 
Day High $2.05    P/E N/A 
Day Low $1.89    EPS $ 
Volume 3,290,497